Sub-system
Gene therapy delivers its payload inside a virus stripped of its ability to replicate. Making enough of that vector, pure enough to inject, has been the constraint on the entire field — more than the biology, more than the clinical evidence, and more than the regulators.
In one sentence
Viral vector manufacturing produces replication-deficient viral particles — most commonly adeno-associated virus for in vivo delivery and lentivirus for cell engineering — carrying a therapeutic genetic payload, purified to clinical standard.
Production means transfecting producer cells with several plasmids that together supply the viral components and the payload, letting the cells assemble particles, then harvesting and purifying them. Yields are low by the standards of protein manufacturing, and doses for systemic delivery are enormous — which is why a single patient can consume an entire manufacturing run.
Purification is the harder half. The harvest contains empty capsids that carry no payload, partially filled ones, host cell material and residual plasmid. Separating full particles from empty ones is difficult because they differ only in what is inside, and the ratio matters clinically — empty capsids contribute immune load without therapeutic effect.
The vector has to reach enough cells in a target tissue, and only a small fraction of injected particles do. Systemic doses are therefore measured in enormous particle counts per kilogram of patient, which converts a low-yield process into a manufacturing problem of a scale that protein therapeutics never faced.
A substantial share of particles produced contain no genetic payload. They are hard to remove because they are nearly identical in size and surface to full ones, and separation relies on small density differences. The full-to-empty ratio is a critical quality attribute, and improving it is one of the most valuable process improvements available.
Each production run consumes grade-controlled plasmid DNA, itself manufactured under regulated conditions with its own lead times. When vector capacity is discussed as a bottleneck, plasmid supply is frequently the layer underneath it — the same recursion this map finds everywhere.
2 of these are marked as a chokepoint: a handful of qualified suppliers, a multi-year lead time, or a single geography.
Every run consumes plasmids manufactured to regulated standards, with their own capacity and lead time.
Nucleic acid reagentsVector production runs almost entirely in disposable systems, sharing that constrained consumable base.
Single-use systemsA run starts as a cell culture that is transfected and left to assemble particles, with the same media, vessels and contamination risk as any other bioreactor.
Cell cultureSeparating full particles from empty ones and from host material is the harder half of the process and where most of the yield is lost.
PurificationThe full-to-empty ratio is a critical quality attribute, and it exists only as a measurement made on every batch.
Analytical instrumentsOther pages in this map that name Viral vector manufacturing as something they cannot do without.
What each company supplies at this step, and — where a public figure exists — its share of this specific market — with what that share measures, the period it covers and who published it. Some rows also show the company’s own reported revenue for the segment covering this step, which is a different thing: it says how much this business matters to that company, not how much of the market it holds. Not a ranking and not a recommendation.
Provides viral vector and cell therapy contract manufacturing.
Supplies vector production and purification technologies.
Provides viral vector and cell therapy contract manufacturing.
Operates vector manufacturing for its own gene therapy programmes.
Manufactures lentiviral and adeno-associated vectors for other companies' programmes, at a scale few independents reach.
Supplies vector manufacturing alongside the testing and release work the batch cannot ship without.
Runs vector and biologics capacity through the contract organisation it has been buying into for a decade.
Runs cell and gene manufacturing sites, now inside a group whose own pipeline competes for the same suites.
Whether yields and full-capsid ratios improve enough to lower cost per dose materially.
Whether plasmid supply expands in step with vector capacity.
Whether producer cell lines replace transient transfection at commercial scale.
Each page explains one technology in plain language, states what it depends on, and names companies by what they supply at that step. Company roles are described qualitatively and deliberately carry no market shares, revenue figures or rankings — those change faster than an explainer can, and a stale number is worse than none. Ticker links point at company pages on this site and are provided for reference only.
Nothing here is investment advice, a recommendation, or a forecast. A company named on a page about a technology is not thereby a good investment, and the chokepoints described are structural facts about supply chains rather than predictions about prices. Technology moves; where a page describes something as unresolved or in development, that was true when it was written.
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal